Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence
Sponsor: Nicole Baca
Trial Details
| Condition | Neurofibromatosis Type 1 |
| Intervention | Whole-body Magnetic Resonance Imaging |
| Phase | NA |
| Status | Recruiting |
| Participants | 15 |
| Est. Completion | 1 May 2028 |
| Last Updated | 7 May 2026 |
Primary Outcome
For scan re-scan reliability, utilize T2 imaging to evaluate the agreement between the baseline scan and the 1 Month scan, which is performed within 4 weeks of the baseline scan.
Eligibility Criteria
Inclusion Criteria
Inclusion Criteria: * Between the ages of 5 and \<18 years at the start of study. If subject will turn 18 during the study, they will be allowed to enroll. * Clinically or molecularly confirmed diagnosis of NF-1. Subjects with mosaic/segmental NF-1 also qualify for the study. Exclusion Criteria: * Requiring sedation for imaging. * Implants and/or Devices: Mechanical, magnetic or electrical activated implants; Ferromagnetic implants and foreign bodies * Claustrophobia, problems being in enclosed spaces, or inability to lie facing upwards. * Allergy to animal dander or animal-instigated asthma.
Trial Sites
Countries
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service